Press Releases

October 13, 2026 – Medicinal Genomics Launches Next-Day Pathogen Testing for Dietary Supplements – Medicinal Genomics today launched a rapid microbial testing solution for dietary supplement manufacturers that delivers next-day pathogen results, compared with the three to five days typical of USP <2022> culture methods. The solution includes three PathoSEEK® multiplex qPCR assays, paired with the MaGiC™ Lysis Kit, to detect Salmonella, Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa.

June 11, 2024 -Medicinal Genomics PathoSEEK® Total Yeast & Mold (TYM) Assay Earns AOAC Certification – Medicinal Genomics Corp. (MGC), a pioneer in harnessing cannabis genomics to improve agricultural productivity, safety, and transparency, today announced that its PathoSEEK® Total Yeast and Mold qPCR Detection Assay with SenSATIVAx DNA Purification received AOAC Performance Tested MethodsSM (PTM) certification, making it the first and only TYM qPCR assay to be approved by AOAC for detection and enumeration of total yeast and mold in dried cannabis flower. The company’s PathoSEEK® qPCR Detection Assays have also been certified for Aspergillus, Salmonella, and Shiga-toxin producing E. coli on a variety of cannabis matrices.

November 08, 2023 – Medicinal Genomics Partners with Bio Molecular Systems to Automate Cannabis Testing -Medicinal Genomics Corp. (MGC), a pioneer in harnessing genomics to improve agricultural productivity, safety, and transparency, today announced a partnership agreement with Bio Molecular Systems (BMS) that would give MGC the right to market BMS’s qPCR Mic instrument, and their liquid handling system, the Myra. This partnership represents a significant addition to the MGC product offering and a robust response to the industry’s critical need to boost cannabis testing accuracy, throughput, and accountability.

April 24, 2023 – Medicinal Genomics Welcomes Cannabis Investors to CannMed 23 Innovation & Investment Summit, May 15-17, Marco Island, FL – “We’re very happy to be able to add the investment component to CannMed 23,” said Brendan McKernan, Medicinal Genomics CEO. “Every new market, especially those with as much potential as this one, attracts a great deal of interest. But it’s also uncharted territory. That’s why we’re thrilled to have a leader with David’s expertise and reputation, and why we’ve had such a great response.”

February 28, 2023 – Medicinal Genomics Unveils Its Compendium of State-by-State Cannabis Microbial Testing Regulations – We at Medicinal Genomics Corporation (MGC) have cataloged the cannabis microbial testing regulations by state as the first step in an effort to shed light on the disarray of the industry’s regulatory status.

February 27, 2023 – Medicinal Genomics Debuts Immersive Workshop Format at CannMed 23 – All the Workshops will be held on Monday, May 15th to allow attendees two full days at the conference proper. As always, CannMed gathers some of the foremost medicinal plant thought leaders, scientists, physicians, and advocates from around the world who will come together to present the latest advances in medicinal plant therapeutics on the conference’s final two days.

September 30, 2022 – New Research Shows that Cannabis Trichomes Trigger Positive Results on Rapid Yeast and Mold Plates – Kevin McKernan, Chief Scientific Officer and Founder of Medicinal Genomics, shares some insight behind his recently published paper related to cannabis trichomes and positive results on rapid yeast and mold plates. In a recent pre-print article by Kevin McKernan and Yvonne Helbert of Medicinal Genomics (1), they present latest findings from their laboratories demonstrating that certain trichome-rich strains can be mistaken for pathogen-rich samples.

June 8, 2022 – A Highly Contiguous Draft Reference Genome for the Psilocybe Cubensis Mushroom Is Now Available – A brief summary of a new peer-reviewed paper detailing the assembly of a highly contiguous draft reference genome for the Psilocybe cubensis mushroom by Kevin McKernan, Medicinal Genomics Chief Science Officer, and colleagues.

June 2, 2022 – How Do You Know You’re Right? qPCR vs. Plating – Cannabis testing to detect microbial contamination is complicated. It may not be rocket science, but it is life science, which means it’s a moving target, or at least, it should be, as we acquire more and more information about how the world we live in works.

May 3, 2022 – Dr. Raphael Mechoulam And Other Cannabis Scientists Attend CannMed 2022 Conference In Pasadena – CannMed, a yearly event to prioritize cannabis science, innovation and collaboration is getting underway in Pasadena, California May 3-5. 

Apr 21, 2022 – Magic Mushrooms Have Over 80 Different Species—And Their DNA Is Now Available Online – Over 42 million bases of the P. cubensis psychedelic mushroom genome were sequenced to fully cover all genes, as well as non-coding regions of the DNA.

March 1st, 2022 – Medicinal Genomics Salmonella and STEC E. coli Multiplex Assay Certified by AOAC – AOAC certified the Medicinal Genomics PathoSEEK® Salmonella and STEC E. coli multiplex assay. The platform now has more cannabis matrices accredited for Aspergillus, Salmonella, and STEC E. coli than any other product, according to a press release.

February 7th, 2022 – Medicinal Genomics Partners with MGI to Promote Automated Agricultural and Medicinal Testing – New collaboration yields genomic technology platforms dedicated to boosting throughput and accuracy.

January 27th, 2022 – Medicinal Genomics Signs Diagnostech as its Distribution Partner in Southern Africa – Nascent Africa medical cannabis markets attract MGC’s advanced testing technology.

August 17th, 2021 – Medicinal Genomics Assay Receives AOAC’s First Certification for Cannabis Flower and Infused Edibles – MGC is the first manufacturer to receive certification for cannabis-infused edibles and is also the first to offer AOAC-approved cannabis assays for two different qPCR machines: Agilent AriaMX and BioRad CFX96.

August 17th, 2021 – AOAC Approves Two New Microbiological Assays – The Medicinal Genomics platform can detect four species, including A. flavus, A. fumigatus, A. niger, and A. terreus in both flower and infused edibles. The PathoSEEK microbial testing platform uses a PCR-based assay and provides an internal plant DNA control for every reaction.

July 1, 2021 – Growth Media Used in Total Yeast and Mold Testing Can Significantly Affect Microbial Diversity, Study Finds – The growth media used in plating-based total yeast and mold count (TYMC) tests can dramatically impact the diversity of microbes that grow, according to a new investigation from scientists at Medicinal Genomics, a specialist cannabis testing and genetics screening firm.

May 18th, 2021 – Medicinal Genomics Hires Sherman Hom as New Director of Regulatory Affairs Medicinal Genomics has hired Sherman Hom, Ph.D. to be their first director of regulatory affairs. Dr. Hom is coming from a position at New Jersey’s Division of Public Health and Environmental Laboratories (PHEL) where he was the leading research scientist for the state’s cannabis testing lab as well as coordinating their pre-analytical activities for SARS-CoV-2 testing.

March 16th, 2021 – Medicinal Genomics Selects Soquimica as its Distribution Partner in Portugal Medicinal Genomics Corp. (MGC), a pioneer in harnessing cannabis genomics to improve the agricultural productivity, safety, and transparency of cannabis, today announced an agreement with Soquimica to be its distribution partner in Portugal.